Psoriasis paves the way for next-generation TYK2 inhibitors in autoimmunity

Two next-generation TYK2 inhibitors are challenging the notion that oral psoriasis therapies cannot achieve the efficacy of injectables, with recent Phase III results from both programs narrowing the gap. As Takeda and Alumis move toward regulatory filings in psoriasis, they are also laying the groundwork for expanding their TYK2 inhibitors into a broader set of autoimmune indications through divergent strategies.

Last month, Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) and Alumis Inc. (NASDAQ:ALMS) presented Phase III data for zasocitinib and envudeucitinib, respectively, at the American Academy of Dermatology Annual Meeting. In both readouts, more than half of treated patients achieved PASI 90, representing at least a 90% improvement from baseline on the Psoriasis Area and Severity Index, marking a step up from the placebo-adjusted 28% PASI 90 rate reported for first-generation TYK2 inhibitor Sotyktu deucravacitinib, marketed by Bristol Myers Squibb Co. (NYSE:BMY)...